(Q38601825)

4 September 2017

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane (English)

1 reference

positron emission tomography

4 September 2017

phase II clinical trial

0 references

1 reference

1 reference

7

1 reference

4 September 2017

H Anderson

1

1 reference

4 September 2017

J T Yap

2

1 reference

4 September 2017

P Wells

3

1 reference

4 September 2017

M P Miller

4

1 reference

4 September 2017

D Propper

5

1 reference

4 September 2017

P Price

6

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

British Journal of Cancer

4 September 2017

1 reference

4 September 2017

89

1 reference

4 September 2017

2

1 reference

4 September 2017

262-267

1 reference

describes a project that uses

4 September 2017

positron emission tomography

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601105

inferred from title

exact match

0 references

cites work

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Clinical measurement of blood flow in tumours using positron emission tomography: a review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

The von Hippel-Lindau tumour suppressor protein: new perspectives

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394254

Control of Malignant Metastases by ICRF 159

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601105

Mode of Action of the Cytostatic Agent ‘ICRF 159’

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601105

Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography

21 January 2018

1 reference

12 December 2020

The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing

1 reference

12 December 2020

Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET

1 reference

12 December 2020

[Microvessel count and vascular endothelial growth factor in renal cell carcinoma]

1 reference

12 December 2020

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis

1 reference

12 December 2020

Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic

1 reference

12 December 2020

Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601105

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference

4 September 2017

PubMed publication ID

12865914

1 reference